Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Total Liabilities (2023 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Total Liabilities for 3 consecutive years, with $14.1 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 54.58% to $14.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.1 million through Dec 2025, up 54.58% year-over-year, with the annual reading at $14.1 million for FY2025, 54.58% up from the prior year.
  • Total Liabilities hit $14.1 million in Q4 2025 for Connect Biopharma Holdings, up from $12.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $25.9 million in Q4 2023 to a low of -$110.9 million in Q2 2024.
  • Historically, Total Liabilities has averaged -$24.8 million across 3 years, with a median of $9.8 million in 2025.
  • Biggest five-year swings in Total Liabilities: plummeted 64.77% in 2024 and later surged 111.91% in 2025.
  • Year by year, Total Liabilities stood at $25.9 million in 2023, then tumbled by 64.77% to $9.1 million in 2024, then soared by 54.58% to $14.1 million in 2025.
  • Business Quant data shows Total Liabilities for CNTB at $14.1 million in Q4 2025, $12.0 million in Q3 2025, and $11.4 million in Q2 2025.